Dosimetric analysis of radiation therapy oncology group 0321: The importance of urethral dose

Practical Radiation Oncology

Volumn 4, Issue 1, 2014, Pages 27-34

  Hsu, I Chow ^a   Hunt, Daniel ^b   Straube, William ^c   Pouliot, Jean ^a   Cunha, Adam ^a   Krishnamurthy, Devan ^a   Sandler, Howard ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RTOG Statistical Center   (United States)

^c Image Guided Therapy Center   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONMETAL;

ARTICLE; CATHETER; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DESCRIPTIVE RESEARCH; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING; UROGENITAL TRACT DISEASE; ANATOMY AND HISTOLOGY; BRACHYTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; MALE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; URETHRA;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; URETHRA;

EID: 84890874430     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2013.02.011     Document Type: Article

References (19)

1. Hsu I.C., Bae K., Shinohara K., et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010, 78:751-758.
2. Lee W.R., Bae K., Lawton C.A., et al. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy 2006, 5:239-243.
3. Charra-Brunaud C., Hsu I.C., Weinberg V., Pouliot J. Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high-dose-rate brachytherapy using a computer model. Int J Radiat Oncol Biol Phys 2003, 56:586-591.
4. (ICRU Report 58) Dose and volume specification for reporting interstitial therapy. Paper presented at: International Commission on Radiation Units and Measurements 1997; Bethesda, MD.
5. Baltas D., Kolotas C., Geramani K., et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998, 40:515-524.
6. Wu A., Ulin K., Sternick E.S. A dose homogeneity index for evaluating 192Ir interstitial breast implant. Med Phys 1988, 15:104-107.
7. Yamada Y., Rogers L., Demanes D.J., et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012, 11:20-32.
8. Ghadjar P., Keller T., Rentsch C.A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
9. Ghadjar P., Matzinger O., Isaak B., et al. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol 2009, 91:237-242.
10. Ishiyama H., Kitano M., Satoh T., et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009, 75:23-28.
11. Sullivan L., Williams S.G., Tai K.H., Foroudi F., Cleeve L., Duchesne G.M. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009, 91:232-236.
12. Ghadjar P., Rentsch C.A., Isaak B., Behrensmeier F., Thalmann G.N., Aebersold D.M. Urethral toxicity vs. cancer control-lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy 2011, 10:286-294.
13. Hindson B.R., Millar J.L., Matheson B. Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors. Brachytherapy 2013, 12:50-55.
14. Morton G.C., Loblaw D.A., Sankreacha R., et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010, 77:811-817.
15. Hoskin P.J., Motohashi K., Bownes P., Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007, 84(2):114-120.
16. Ménard C., Susil R.C., Choyke P., et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 2004, 59:1414-1423.
17. Pouliot J., Kim Y., Lessard E., Hsu I.C., Vigneron D.B., Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004, 59:1196-1207.
18. Kim Y., Hsu I.C., Lessard E., Kurhanewicz J., Noworolski S.M., Pouliot J. Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol 2008, 88:148-155.
19. Cunha J.A., Pouliot J., Weinberg V., Wang-Chesebro A., Roach M., Hsu I.C. Urethra low-dose tunnels: Validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy 2012, 11:348-353.